GEN Exclusives

More »

GEN News Highlights

More »
Jan 11, 2007

Court Permanently Halts Abbott's Sale of HCV Genotyping Products for Infringing Innogenetics' Patent

  • Innogenetics reported that a U.S. court entered a permanent injunction against Abbott Laboratories, prohibiting the company from selling or using products, including components, that infringe on Innogenetics' patented Hepatitis C Virus  genotyping technology. The injunction also prevents Abbott from exporting components of the infringing products to foreign countries.

    In September 2006 a jury unanimously found that Abbott had willfully infringed Innogenetics' U.S. patent 5,846,704 and awarded the company $7 million in damages.

    The U.S. District Court for the Western District of Wisconsin made the ruling at the close of an evidentiary hearing to determine the potential public impact of a permanent injunction against Abbott. Last week, the court found that Innogenetics suffered irreparable harm from Abbott's infringement.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?